Proof-of-Concept Study of Ivacaftor Monotherapy Showed Improvements in Lung Function After Two Weeks of Treatment in People with Cystic Fibrosis who have a Residual Function Mutation

Data are consistent with in vitro observations in residual function mutations showing that ivacaftor improved CFTR activity 8-week open-label period showed improvements in lung function Data support plans to initiate a Phase 3 study of ivacaftor in people with CF … Continued